News & Updates
Filter by Specialty:
Novel drug helps lessen liver stiffness in high-risk NAFLD
Treatment with the novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα) pemafibrate appears to produce a significant reduction in liver stiffness but not in liver fat content in patients with high-risk nonalcoholic fatty liver disease (NAFLD), according to the results of a phase II trial.
Novel drug helps lessen liver stiffness in high-risk NAFLD
07 Oct 2021
HCC in SG: NASH aetiology on the rise, curative therapy more accessible
Hepatocellular carcinoma (HCC) in Singapore has changed markedly throughout the last decade, with patients being diagnosed at an increasingly older age and cryptogenic cirrhosis/nonalcoholic steatohepatitis (NASH) becoming a more important aetiology, according to a recent study.
HCC in SG: NASH aetiology on the rise, curative therapy more accessible
05 Oct 2021
Collagen proportionate area predicts long-term, but not short-term mortality in alcoholic hepatitis
Collagen proportionate area (CPA) is a good predictor of long-term mortality in alcoholic hepatitis (AH) patients regardless of their abstinence from alcohol, a recent study has found. However, CPA seems to have no clear interaction with short-term mortality.
